Sangamo Therapeutics, Inc. (SGMO)

Market Cap	143.80M -44.0%
Revenue (ttm)	32.88M -37.1%
Net Income	-108.91M
EPS	-0.44
Shares Out	371.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,578,570
Open	0.3827
Previous Close	0.3788
Day's Range	0.3751 - 0.4058
52-Week Range	0.3450 - 1.2380
Beta	1.31
Analysts	Buy
Price Target	5.75 (+1,386.17%)
Earnings Date	Mar 16, 2026

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 183
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO
• Website: https://www.sangamo.com

Financial Performance

In 2024, Sangamo Therapeutics's revenue was $57.80 million, a decrease of -67.20% compared to the previous year's $176.23 million. Losses were -$97.94 million, -62.01% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price target is $5.75, which is an increase of 1,386.17% from the latest price.

Price Target

$5.75

(1,386.17% upside)

Analyst Consensus: Buy